Prognostic value of pre-operative serum CA 15.3 levels in breast cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3965-3971

  Martín, Arancha ^a,b   Corte, Ma Daniela ^a,b   Álvarez, Ana Ma ^c   Rodriguez, Juan Carlos ^a,b   Andicoechea, Alejandro ^b   Bongera, Miguel ^b   Junquera, Sara ^b   Pidal, Diego ^b   Allende, Ma Teresa ^a,c   Muñiz, José L García ^a,c   Vizoso, Francisco ^a,b  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL DE JOVE   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Breast cancer; MUC 1; Prognosis; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; PROGNOSIS; RECURRENCE;

EID: 33750705887     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Agrawal B, Krantz MJ, Reddish MA and Longenecker BM: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4: 43-49, 1998.
2. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
3. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
4. Duffy MJ: CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36(Pt 5): 579-586, 1999.
5. Fehm T, Jager W, Kramer S, Sohn C, Slomayer E, Wallwiener D and Gebaver G: Prognostic significance of serum HER2 and CA 15.3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24: 1987-1992, 2004.
6. Fung PY and Longenecker BM: Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51: 1170-1176, 1991.
7. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW and Nadler LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2: 1367-1370, 1996.
8. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, Gatti C, Paccagnella A and Marubini E: Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38: 1181-1188, 2002.
9. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K and Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37: 355-363, 2001.
10. Hedley DW, Shankey TV and Wheeless LL: DNA cytometry consensus conference. Cytometry 14: 471, 1993.
11. Hilkens J, Ligtenberg MJ, Vos HL and Litvinov SV: Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 17: 359-363, 1992.
12. Horobin JM, Browning MC, McFarlane NP, Smith G, Preece PE, Wood RA and Cuschieri A: Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 36: 219-221, 1991.
13. Iaffaioli RV, Caponigro F, Esposito G, Pagliarulo C, Deplacido S, Ungaro B, Bazzicalupo L, Frasci G and Bianco AR: Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers 6: 21-24, 1991.
14. Kumpulainen EJ, Keskikuru RJ and Johansson RT: Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76: 95-102, 2002.
15. Lumachi F, Bass SM, Brandes AA, Pagano D and Ermani M: Relationship between tumor markers CEA and CA15.3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pTl-2 breast cancer. Anticancer Res 24: 3221-3224, 2004.
16. MacLean GD, Reddish MA, Koganty RR and Longenecker BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19: 59-68, 1996.
17. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farms B and Ballesta AM: Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 23: 1035-1041, 2003.
18. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farms B, Latre ML, Escriche C, Estape J and Ballesta AM: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51: 109-119, 1998.
19. Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP and van Diest PJ: Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int J Cancer 84: 466-469, 1999.
20. Nicolini A, Anselmi L, Michelassi C and Carpi A: Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 76: 1106-1111, 1997.
21. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H and Given HF: An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 77: 1288-1291, 1995.
22. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JR, Gronberg H, Kumpulainen E and Blarney RW: The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 35: 47-53, 1999.
23. Safi F, Kohler I, Rottinger E and Beger H: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 68: 574-582, 1991.
24. Shering SG, Sherry F, McDermott EW, O'Higgins NJ and Duffy MJ: Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 83: 2521-2527, 1998.
25. Spicer AP, Rowse GJ, Lidner TK and Gendler SJ: Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 270: 30093-30101, 1995.
26. Taylor-Papadimitriou J, Burchell J, Miles DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta 1455: 301-313, 1999.
27. Tondini C, Hayes DF, Gelman R, Henderson IC and Kufe DW: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48: 4107-4112, 1988.
28. Tornamira M, Montero S, Vargas C, Guzman C, Cortes-Funes H and Colomer R: Preoperative CA 15.3 and prognosis in primary breast cancer. Rev Oncologia 2: 316-319, 2000.
29. Vizcarra E, Lluch A, Cibrian R, Jarque F and Garcia-Conde J: CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51: 491-496, 1994.